KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Amortization - Intangibles (2017 - 2025)

Sarepta Therapeutics has reported Amortization - Intangibles over the past 9 years, most recently at $677000.0 for Q4 2025.

  • For Q4 2025, Amortization - Intangibles rose 12.65% year-over-year to $677000.0; the TTM value through Dec 2025 reached $2.6 million, up 9.02%, while the annual FY2025 figure was $2.6 million, 9.02% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $677000.0 at Sarepta Therapeutics, roughly flat from $677000.0 in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $763000.0 in Q4 2023 and troughed at $170000.0 in Q1 2021.
  • A 5-year average of $400300.0 and a median of $309000.0 in 2021 define the central range for Amortization - Intangibles.
  • Biggest five-year swings in Amortization - Intangibles: soared 326.26% in 2023 and later fell 21.23% in 2024.
  • Year by year, Amortization - Intangibles stood at $179000.0 in 2021, then changed by 0.0% to $179000.0 in 2022, then skyrocketed by 326.26% to $763000.0 in 2023, then fell by 21.23% to $601000.0 in 2024, then rose by 12.65% to $677000.0 in 2025.
  • Business Quant data shows Amortization - Intangibles for SRPT at $677000.0 in Q4 2025, $677000.0 in Q3 2025, and $667000.0 in Q2 2025.